Kanada - Prancis - Health Canada

ino therapeutics - monoxyde d'azote - gaz - 800ppm - monoxyde d'azote 800ppm - nitrates and nitrites

Kanada - Prancis - Health Canada

airgas therapeutics llc - monoxyde d'azote - gaz - 100ppm - monoxyde d'azote 100ppm - nitrates and nitrites

Kanada - Prancis - Health Canada

airgas therapeutics llc - monoxyde d'azote - gaz - 800ppm - monoxyde d'azote 800ppm - nitrates and nitrites

Kanada - Prancis - Health Canada

praxair canada inc - monoxyde d'azote - gaz - 100ppm - monoxyde d'azote 100ppm - nitrates and nitrites

Kanada - Prancis - Health Canada

praxair canada inc - monoxyde d'azote - gaz - 800ppm - monoxyde d'azote 800ppm - nitrates and nitrites

Swiss - Prancis - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - lumacaftorum, ivacaftorum - comprimés pelliculés - lumacaftorum 100 mg, ivacaftorum 125 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, carmellosum natricum conexum, povidonum k 30, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 120, e 132, e 133, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum pro compresso obducto corresp. natrium 2.56 mg. - la mucoviscidose - synthetika

Uni Eropa - Prancis - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, l'ivacaftor - fibrose kystique - autres produits du système respiratoire - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Swiss - Prancis - Swissmedic (Swiss Agency for Therapeutic Products)

vertex pharmaceuticals (ch) gmbh - tezacaftorum, ivacaftorum - comprimés pelliculés - filmtablette morgendosis (tezacaftorum 100 mg / ivacaftorum 150 mg): tezacaftorum 100 mg, ivacaftorum 150 mg, hypromellosi acetas succinas, natrii laurilsulfas, hypromellosum, cellulosum microcristallinum, carmellosum natricum conexum, magnesii stearas, Überzug: hypromellosum, hydroxypropylcellulosum, talcum, e 171, e 172 (flavum) pro compresso obducto corresp. natrium 2.74 mg. filmtablette abenddosis (ivacaftorum 150 mg): ivacaftorum 150 mg, hypromellosi acetas succinas, natrii laurilsulfas, cellulosum microcristallinum, lactosum monohydricum 167.2 mg, carmellosum natricum conexum, silica colloidalis anhydrica, magnesii stearas, Überzug: poly(alcohol vinylicus), e 171, macrogolum 3350, talcum, e 132, cera carnauba, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammonii hydroxidum pro compresso obducto corresp. natrium 1.82 mg. - traitement de la fibrose kystique - synthetika

Belgia - Prancis - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sol s.p.a. - monoxyde d'azote 225 ppm - gaz médicinal comprimé - 225 ppm mol/mol - monoxyde d'azote - nitric oxide

Belgia - Prancis - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sol s.p.a. - monoxyde d'azote 450 ppm - gaz médicinal comprimé - 450 ppm mol/mol - monoxyde d'azote - nitric oxide